Primary Care, Population Sciences, and Medical Education, University of Southampton, Aldermoor Health Centre, Southampton, SO16 5ST, UK.
Department of Health Sciences, University of Leicester, George Davies Centre, University Road Leicester, Leicester, LE1 7RH, UK.
Trials. 2020 May 29;21(1):441. doi: 10.1186/s13063-020-04344-9.
Benefits to patients from reduced depression have been shown from monitoring progress with patient-reported outcome measures (PROMs) in psychological therapy and mental health settings. This approach has not yet been researched in the United Kingdom for primary care, which is where most people with depression are treated in the United Kingdom.
This is a parallel-group cluster randomised trial with 1:1 allocation to intervention and control. Patients who are age 18+ years, with a new episode of depressive disorder/symptoms, meet the inclusion criteria. Patients with current depression treatment, comorbid dementia/psychosis/substance misuse/suicidal ideas are excluded. The intervention includes the Administration of Patient Health Questionnaire (PHQ-9) as a PROM within 2 weeks of diagnosis and at follow-up 4 weeks later. General practitioners are trained in interpreting scores and asked to take them into account in their treatment decisions. Patients are given written feedback on scores and suggested treatments. The primary outcome measure is Depression on the Beck Depression Inventory BDI-II at 12 weeks. Secondary outcomes include BDI-II at 26 weeks, changes in drug treatments and referrals, social functioning (Work & Social Adjustment Scale) and quality of life (EQ-5D) at 12 and 26 weeks, service use over 26 weeks (modified Client Services Receipt Inventory) to calculate NHS costs, and patient satisfaction at 26 weeks (Medical Informant Satisfaction Scale). The sample includes 676 total participants from 113 practices across three centres. Randomisation is achieved by computerised sequence generation. Blinding is impossible given the nature of the intervention (self-report outcome measures prevent rating bias). Differences at 12 and 26 weeks between intervention and controls in depression, social functioning and quality of life are analysed using linear mixed models, adjusted for socio-demographics, baseline depression, anxiety, and clustering, while including practice as a random effect. Patient satisfaction, quality of life (QALYs) and costs over 26 weeks will be compared between arms. Qualitative process analysis includes interviews with 15-20 GP/NPs and 15-20 patients per arm to reflect trial results and implementation issues, using Normalization Process Theory as a theoretical framework.
If PROMs are helpful in improving patient outcomes for depression even to a small extent, then they are likely to be good value for money, given their low cost. The benefits could be considerable, given that depression is common, disabling, and costly.
ISRCTN no: 17299295. Registered 1st October 2018.
在心理治疗和精神卫生环境中,通过患者报告的结果测量(PROMs)监测进展,已显示对患者的抑郁减轻有好处。在英国,这种方法尚未在初级保健中进行研究,而在英国,大多数抑郁症患者都在那里接受治疗。
这是一项平行分组的群组随机试验,干预组和对照组的分配比例为 1:1。纳入标准为年龄在 18 岁及以上,新出现抑郁障碍/症状的患者。目前正在接受抑郁治疗、共病痴呆/精神病/物质滥用/自杀意念的患者被排除在外。干预措施包括在诊断后 2 周内使用患者健康问卷(PHQ-9)作为 PROM,并在 4 周后的随访中进行。全科医生接受了解释分数的培训,并被要求在治疗决策中考虑这些分数。患者会收到分数和建议治疗的书面反馈。主要结局测量是在 12 周时贝克抑郁量表(BDI-II)的抑郁程度。次要结局包括在 26 周时 BDI-II、药物治疗和转诊的变化、社会功能(工作和社会调整量表)和生活质量(EQ-5D)在 12 周和 26 周时、26 周时的服务使用(修改后的客户服务接收清单)以计算 NHS 成本,以及 26 周时的患者满意度(医疗信息员满意度量表)。该样本包括来自三个中心的 113 个实践中的 676 名参与者。通过计算机化序列生成实现随机分组。由于干预的性质(自我报告的结果测量可防止评分偏差),无法进行盲法。使用线性混合模型分析干预组和对照组在抑郁、社会功能和生活质量方面在 12 周和 26 周时的差异,调整了社会人口统计学因素、基线抑郁、焦虑和聚类,同时将实践作为随机效应。将比较 26 周时臂间的患者满意度、生活质量(QALYs)和成本。定性过程分析包括对每组 15-20 名全科医生/家庭医生和 15-20 名患者进行访谈,以反映试验结果和实施问题,使用正常化过程理论作为理论框架。
如果 PROMs 对改善抑郁症患者的预后有帮助,即使只有很小的帮助,那么考虑到它们的低成本,它们很可能是物有所值的。鉴于抑郁症很常见、使人丧失能力且成本高昂,那么这些好处可能相当可观。
ISRCTN 编号:17299295。于 2018 年 10 月 1 日注册。